Department of Medicinal Chemistry, School of Pharmacy, Qingdao University, Qingdao, Shandong, China.
Department of Pharmacology, College of Basic Medicine, Qingdao University, Qingdao, Shandong, China.
Bioorg Med Chem Lett. 2019 Sep 15;29(18):2638-2645. doi: 10.1016/j.bmcl.2019.07.045. Epub 2019 Jul 24.
Histone deacetylases (HDACs) have proven to be promising targets for the development of anti-cancer drugs. In this study, we reported a series of novel chalcone based tubulin and HDAC dual-targeting inhibitors. Three compounds inhibited the activities of HDAC and tubulin polymerization simultaneously and displayed anti-proliferative activities toward eleven human tumor cell lines. Compound 8a remarkably induced growth inhibition, apoptosis and G2/M phase arrest of A549 tumor cells. Finally, the inhibitory activities of 8a against HDAC6 and tubulin were rationalized by molecular docking studies.
组蛋白去乙酰化酶(HDACs)已被证明是开发抗癌药物的有前途的靶点。在这项研究中,我们报道了一系列新型基于查尔酮的微管蛋白和 HDAC 双重靶向抑制剂。三种化合物同时抑制 HDAC 和微管蛋白聚合的活性,并对 11 种人肿瘤细胞系表现出抗增殖活性。化合物 8a 显著诱导 A549 肿瘤细胞的生长抑制、凋亡和 G2/M 期阻滞。最后,通过分子对接研究合理地解释了 8a 对 HDAC6 和微管蛋白的抑制活性。